BIO Valuation - Is Bio-Rad Laboratories Inc Over or Undervalued?
Comprehensive analysis of Bio-Rad Laboratories Inc valuation metrics including P/E, P/B, P/S, and EV/EBITDA ratios
Current Stock Price
$278.44
Market Cap
$7.52B
Valuation Date
Feb 28, 2026
Valuation Verdict
Potentially Undervalued
Based on valuation multiples, BIO appears attractively priced. 3 key metrics suggest potential value opportunity.
Key Valuation Metrics
These four fundamental valuation ratios help determine if BIO is trading at a fair price relative to its earnings, assets, revenue, and cash flow generation.
How to Interpret These Metrics
How BIO Compares to Peers
What This Means for Investors
Potential Value Opportunity
Bio-Rad Laboratories Inc (BIO) currently trades at valuation multiples that appear attractive relative to historical averages and peer comparisons. This could represent a buying opportunity for long-term investors who believe in the company's fundamentals. However, always investigate why the market is pricing the stock this way - there may be legitimate concerns about future growth or profitability.
Bullish Considerations
- P/E ratio below market average
- Reasonable price relative to book value
- Attractive price-to-sales multiple
- Favorable EV/EBITDA valuation
- Multiple metrics suggest undervaluation
Bearish Considerations
Complete Your Analysis
Valuation is just one piece of the puzzle. Get the complete picture of BIO with our comprehensive analysis tools.
Full Stock Analysis
Complete financials, charts, and metrics
Should I Buy BIO?
AI-powered investment recommendation
Price Forecast
Future price targets and predictions
Analyst Ratings
Wall Street consensus and targets
Deep Valuation Analysis
DCF model and intrinsic value
Latest News
Breaking news and market sentiment
Frequently Asked Questions
What is BIO's P/E ratio and what does it mean?
BIO has a P/E (Price-to-Earnings) ratio of 10.00. This means investors are paying $10.00 for every $1 of annual earnings. A lower P/E generally suggests better value, but it's important to compare against industry peers and growth prospects. The market average P/E is typically 15-20x.
Is BIO stock overvalued or undervalued?
Based on our analysis of key valuation metrics (P/E, P/B, P/S, EV/EBITDA), BIO appears potentially undervalued. Based on valuation multiples, BIO appears attractively priced. 3 key metrics suggest potential value opportunity. However, valuation is just one factor to consider alongside growth prospects, competitive position, and market conditions.
What is a good P/E ratio for BIO?
There's no single "good" P/E ratio as it varies by industry and growth stage. For Bio-Rad Laboratories Inc, compare the current P/E of 10.00 against: (1) Industry peers, (2) Historical average P/E for BIO, (3) Expected earnings growth rate. High-growth companies often justify higher P/E ratios, while mature companies typically trade at lower multiples.
How do I use valuation ratios to make investment decisions?
Valuation ratios are screening tools, not buy/sell signals. Use them to: (1) Compare BIO against competitors, (2) Identify potential over/undervaluation, (3) Understand what you're paying for earnings, assets, or sales. Combine valuation analysis with fundamental research, growth prospects, and technical analysis for comprehensive decision-making.
What is EV/EBITDA and why does it matter?
EV/EBITDA (Enterprise Value to EBITDA) is 5.99 for BIO. This ratio is useful because it accounts for debt and excludes non-cash expenses, making it better for comparing companies with different capital structures. Lower EV/EBITDA generally indicates better value. It's particularly useful for comparing companies in capital-intensive industries.
Disclaimer: This valuation analysis is for informational and educational purposes only and should not be considered investment advice. Valuation metrics are just one factor in investment decisions. Always conduct comprehensive research and consult with a qualified financial advisor before making investment decisions. Past performance and current valuations do not guarantee future results.